Drug screening in human plasma by cloud-point extraction and HPLC

• Authors: Katarzyna Madej , Karolina Persona
• Languages of publication: EN

Abstracts

EN

Cloud-point extraction (CPE) with RP-HPLC/DAD detection was used to develop a screen for six model basic drugs (paracetamol, promazine, amitriptyline, nortriptyline, clomipramine and chlorpromazine) in human plasma. These drugs’ varied hydrophobicities entail different affinities for the micelle-rich phase and CPE extraction efficiencies. Extraction recovery (except paracetamol) was above 80% and reproducibility (RSD%) ranged from 2.88 to 10.26 intraday and from 3.12 to 12.33 interday. The limits of detection were: 0.125 µg mL−1 (promazine and chlorpromazine), 0.25 µg mL−1 (amitriptyline and nortriptyline) and 0.5 µg mL−1 (paracetamol and clomipramine). The method was linear over the ranges: 0.125–1.0 µg mL−1 (promazine and chlorpromazine), 0.25–1.0 µg mL−1 (amitriptyline and nortriptyline), 0.5–1.0 µg mL−1 (clomipramine) and 0.5–10 µg mL−1 (paracetamol). The procedure is a good alternative to the SPE or LLE sample preparation usually used.

Keywords

EN

Cloud-point extraction; Micelle-mediated extraction; Screening HPLC analysis; Basic drugs

• Publisher: De Gruyter Open
• Journal: Open Chemistry
• Year: 2013
• Volume: 11
• Issue: 1
• Pages: 94-100

Dates

published

1 - 1 - 2013

online

24 - 10 - 2012

Contributors

author

Katarzyna Madej

• Jagiellonian University

author

Karolina Persona

• Jagiellonian University

References

• [1] A.C. Moffat, M.D. Osselton, B. Widdop (Eds.), Clarke’s Analysis of Drugs and Poisons, 3rd edition (Pharmaceutical Press, London, 2004)
• [2] L. Mercolini, R. Mandrioli, G. Finizio, G. Boncompagni, M.A. Raggi, J. Sep. Sci. 33, 23 (2010) http://dx.doi.org/10.1002/jssc.200900493[Crossref]
• [3] L. Mercolini, M. Grillo, C. Bartoletti, G. Boncompagni, M.A. Raggi, Anal. Bioanal. Chem. 388, 235 (2007) http://dx.doi.org/10.1007/s00216-007-1195-1[Crossref]
• [4] G. Zhang, A.V. Terry Jr., M.G. Bartlett, J. Chromatogr. B 856, 20 (2007) http://dx.doi.org/10.1016/j.jchromb.2007.05.015[Crossref]
• [5] C. Flores-Pérez, J.L. Chávez-Pacheco, B. Ramírez-Mendiola, R. Alemón-Medina, R. García-Álvarez, H. Juárez-Olguín, J. Flores-Pérez, Chromatography 25, 760 (2011)
• [6] K. Madej, Trends Anal. Chem. 28, 436 (2009) http://dx.doi.org/10.1016/j.trac.2009.02.002[Crossref]
• [7] Z.-m. Zhou, D.-y. Zhao, J. Wang, W.-j. Zhao, M.-m. Yang, J. Chromatogr. A 30, 1216 (2009)
• [8] Ch.Ch. Wang, M.O. Luconi, A.N. Masi, L. Fernández, Talanta 72, 1779 (2007) http://dx.doi.org/10.1016/j.talanta.2007.02.010[Crossref]
• [9] H. Wu, G.-Y. Zhao, L.-M. Du, Spectrochim. Acta A 75, 1624 (2010) http://dx.doi.org/10.1016/j.saa.2010.02.031[Crossref]
• [10] H. Filik, İ. Şener, S.D. Cekiç, E. Kiliç, R. Apak, Chem. Pharm. Bull. 54, 891 (2006) http://dx.doi.org/10.1248/cpb.54.891[Crossref]
• [11] A.B. Tabrizi, Bull. Korean Chem. Soc. 27, 1604 (2006) http://dx.doi.org/10.5012/bkcs.2006.27.10.1604[Crossref]
• [12] H. Zhang, H.-K. Choi, Anal. Bioanal. Chem. 392, 947 (2008) http://dx.doi.org/10.1007/s00216-008-2333-0[Crossref]
• [13] A. Ohashi, M. Ogiwara, R. Kieda, H. Okada, K. Ohashi, Anal. Sci. 20, 1353 (2004) http://dx.doi.org/10.2116/analsci.20.1353[Crossref]
• [14] M.H. Mashhadizadeh, L. Jafari, J. Iran. Chem. Soc. 7, 678 (2010) http://dx.doi.org/10.1007/BF03246057[Crossref]
• [15] F. Han, R. Yin, X.-l. Shi, Q. Jia, H.-z. Liu, H.-m. Yao, L. Xu, S.-m. Li, J. Chromatogr. B, 868, 64 (2008) http://dx.doi.org/10.1016/j.jchromb.2008.04.024[Crossref]
• [16] W. Liu, K. Bi, X. Liu, J. Zhao, X. Chen, Chromatographia 69, 837 (2009) http://dx.doi.org/10.1365/s10337-009-1027-x[Crossref]
• [17] J. Zhou, P. Zeng, H. H. Tu, F. Q. Wang, J. Sep. Sci. 34, 160 (2011) http://dx.doi.org/10.1002/jssc.201000382[Crossref]
• [18] K. Madej, K. Persona, M. Nizio, Acta Chromatographica 1, 1 (2013)

Identifiers

DOI

10.2478/s11532-012-0134-y